Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

NCT00463203 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Brain Neoplasms
Glioma

Interventions

DRUG: Bevacizumab
DRUG: Irinotecan

Sponsor

Rigshospitalet, Denmark